Literature DB >> 14605005

Activation of the retinoid X receptor suppresses appetite in the rat.

Kathleen M Ogilvie1, Régis Saladin, Tim R Nagy, Mary S Urcan, Richard A Heyman, Mark D Leibowitz.   

Abstract

The retinoid X receptor (RXR), a ubiquitously expressed intracellular receptor, regulates pathways controlling glucose, triglycerides, cholesterol, and bile acid metabolism. In addition to its role in those metabolic pathways, we reported that RXR activation with a pan agonist [e.g. LG100268 (LG268)] decreases both body weight gain (BWG) and food consumption (FC) in obese, insulin-resistant rodents. In parallel with those changes in energy balance, we show here that activation of RXR pathways results in adipose tissue remodeling, particularly within sc fat where the rate of apoptosis is increased 5-fold. This change may underlie the selective decrease in fat mass observed in Zucker fatty rats treated with LG268 for 6 wk. Because FC is strongly correlated with BWG in treated animals, we hypothesized that regulation of FC might be the primary mechanism underlying reduced BWG during RXR agonist administration. Importantly, decreased FC is due to decreased meal size, suggestive of induced satiety rather than malaise and/or aversion to food. Furthermore, administration of LG268 directly into the brain via intracerebroventricular injection also reduces FC, BWG, and insulin, whereas the elevation in triglycerides observed after oral administration is absent. The latter observation suggests that RXR actions on energy balance and lipid homeostasis are separable. Therefore, ligand-mediated activation of either an RXR homodimer or an unidentified heterodimeric complex regulates pathways controlling energy balance at least in part via a central nervous system-mediated mechanism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14605005     DOI: 10.1210/en.2003-0907

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  12 in total

Review 1.  The retinoid X receptors and their ligands.

Authors:  Marcia I Dawson; Zebin Xia
Journal:  Biochim Biophys Acta       Date:  2011-10-01

2.  CCK-8 and CCK-58 differ in their effects on nocturnal solid meal pattern in undisturbed rats.

Authors:  Miriam Goebel-Stengel; Andreas Stengel; Lixin Wang; Gordon Ohning; Yvette Taché; Joseph R Reeve
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-08-08       Impact factor: 3.619

Review 3.  Drugs that suppress TSH or cause central hypothyroidism.

Authors:  Bryan R Haugen
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-12       Impact factor: 4.690

Review 4.  Nuclear receptors, mitochondria and lipid metabolism.

Authors:  William A Alaynick
Journal:  Mitochondrion       Date:  2008-02-26       Impact factor: 4.160

5.  Retinoid X Receptor Activation During Adipogenesis of Female Mesenchymal Stem Cells Programs a Dysfunctional Adipocyte.

Authors:  Bassem M Shoucri; Victor T Hung; Raquel Chamorro-García; Toshi Shioda; Bruce Blumberg
Journal:  Endocrinology       Date:  2018-08-01       Impact factor: 4.736

Review 6.  Brain nuclear receptors and body weight regulation.

Authors:  Yong Xu; Bert W O'Malley; Joel K Elmquist
Journal:  J Clin Invest       Date:  2017-02-20       Impact factor: 14.808

7.  Retinoid metabolism and diabetes mellitus.

Authors:  Eun-Jung Rhee; Jorge Plutzky
Journal:  Diabetes Metab J       Date:  2012-06-14       Impact factor: 5.376

8.  A Small Molecule, UAB126, Reverses Diet-Induced Obesity and its Associated Metabolic Disorders.

Authors:  Guang Ren; Teayoun Kim; Hae-Suk Kim; Martin E Young; Donald D Muccio; Venkatram R Atigadda; Samuel I Blum; Hubert M Tse; Kirk M Habegger; Sushant Bhatnagar; Tatjana Coric; Mary-Ann Bjornsti; Anath Shalev; Stuart J Frank; Jeong-A Kim
Journal:  Diabetes       Date:  2020-07-01       Impact factor: 9.337

9.  Therapeutic potential of retinoid x receptor modulators for the treatment of the metabolic syndrome.

Authors:  Jane A Pinaire; Anne Reifel-Miller
Journal:  PPAR Res       Date:  2007-03-28       Impact factor: 4.964

10.  Identification of Bexarotene as a PPARγ Antagonist with HDX.

Authors:  David P Marciano; Dana S Kuruvilla; Bruce D Pascal; Patrick R Griffin
Journal:  PPAR Res       Date:  2015-09-15       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.